Neurocrine Biosciences (NBIX) Retained Earnings (2010 - 2026)
Neurocrine Biosciences (NBIX) posted Retained Earnings of $589.6 million for Q1 2026, up 31.7% on a QoQ basis from $447.7 million in Q4 2025, and up 6451.11% year-over-year from $9.0 million in Q1 2025.
Neurocrine Biosciences (NBIX) Retained Earnings (2010 - 2026) Analysis & Trends
Neurocrine Biosciences' Retained Earnings history runs 17 years deep, the most recent figure standing at $589.6 million for Q1 2026.
- Quarterly Retained Earnings rose 6451.11% year-over-year to $589.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $589.6 million (up 6451.11% YoY) and the FY2025 annual result came in at $447.7 million, up 7618.97% from the prior year.
- Retained Earnings was $589.6 million for Q1 2026 at Neurocrine Biosciences, up from $447.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at $589.6 million in Q1 2026 and bottomed at -$564.3 million in Q2 2022.
- A 5-year average of -$71.3 million and a median of -$1.1 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings tumbled 124050.0% — and 2025, when it jumped 7618.97%.
- Neurocrine Biosciences' Retained Earnings stood at -$7.9 million in 2022, then slumped by 1888.61% to -$157.1 million in 2023, then jumped by 103.69% to $5.8 million in 2024, then soared by 7618.97% to $447.7 million in 2025, then soared by 31.7% to $589.6 million in 2026.
- Business Quant data shows NBIX's Retained Earnings at $589.6 million in Q1 2026, $447.7 million in Q4 2025, and $13.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -319.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 589.60 Mn |
| Dec 31, 2025 | 447.70 Mn |
| Sep 30, 2025 | 13.20 Mn |
| Jun 30, 2025 | 12.50 Mn |
| Mar 31, 2025 | 9.00 Mn |
| Dec 31, 2024 | 5.80 Mn |
| Sep 30, 2024 | 14.50 Mn |
| Jun 30, 2024 | -48.70 Mn |
| Mar 31, 2024 | 3.30 Mn |
| Dec 31, 2023 | -157.10 Mn |
| Sep 30, 2023 | -1.70 Mn |
| Jun 30, 2023 | -1.10 Mn |
| Mar 31, 2023 | -483.40 Mn |
| Dec 31, 2022 | -7.90 Mn |
| Sep 30, 2022 | -495.80 Mn |
| Jun 30, 2022 | -564.30 Mn |
| Mar 31, 2022 | -547.40 Mn |
| Dec 31, 2021 | -1.70 Mn |
| Sep 30, 2021 | 400,000.00 |
| Jun 30, 2021 | -651.00 Mn |